🔗 Share this article

As the United States proceeds with unprecedented adjustments to its immunization guidelines, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American physician and public health researcher who first made her name by expressing skepticism about Covid vaccinations during the global health crisis and has zeroed in on potential fatalities following Covid vaccination in her recent position at the FDA.

Proposed Changes to Childhood Immunization Program

Public health authorities were set to reveal radical revisions to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would place the US out of step with much of the international standard with insufficient data for improved outcomes. The announcement has been delayed until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad solidify control at the agency – and it signals a renewed priority upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific pediatric immunization guidelines in the US so as to align more in line with Denmark's approach, a nation with comprehensive healthcare and a population about the size of Wisconsin’s.

To date comments, she has kept her attention on immunizations – typically the domain of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

The appointee has no apparent experience in pharmaceutical research, approval processes or leadership, which has been standard for previous leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, remarked a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in leading a sizeable institution. She is not an expert in drug approvals.”

Previous commissioners of the center would “grasp regulatory frameworks and the research of drug development”, said Janet Woodcock. “Objectively, she doesn’t have the kind of background that previous people who ran the center have had.”

This division has an immense workload at the FDA, she emphasized.

“The public just zeroes in on the innovative therapies, but the off-patent medication office clears a multitude of generic medications. There is also a biosimilars program, non-prescription drug unit and so forth, and each of these must be supervised,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a major leadership aspect to the position, which oversees more than 5,000 employees. “It is a huge leadership role, if you perform it correctly,” she added.

Official Statement and Controversial Programs

In response to questions about Høeg’s qualifications and whether this assignment indicates more teamwork among regulatory chiefs on immunizations, a press secretary responded that the “questions are based on inaccurate presumptions”.

“Her resume is consistent with the responsibilities of her job,” the representative explained, pointing to the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial priority voucher program, a disputed expedited medication authorization process that reportedly worried her predecessors. “How are these medications being picked for this expedited pathway? Who is making the decisions?” Howard questioned. “There’s a lot of secrecy going on at the agency right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards more relaxed rules of pharmaceuticals, with the exception of vaccines.”

Documented History on Vaccines

Concerning vaccines, Høeg has a more documented, if problematic, history, critics said. She authored a study using non-validated volunteer-provided data to determine the rate of myocarditis following Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are more dangerous than they are.

Among her “policy goals” for the new administration featured altering regulations for new vaccines and discontinuing “optional” vaccines, she remarked after the election on a podcast. At the agency, Høeg has reportedly proposed preventing adolescent males from obtaining Covid vaccinations.

“She’s an thorough ideologue who commences with her conclusions and works backwards to retrofit the evidence in a very disingenuous, dishonest way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow skeptics, {like|